stores-spontaneously generates rhythmic local Ca 2+ oscillations, a phenomenon sometimes referred to as a 'calcium clock' . The ensemble of these rhythmic local Ca 2+ releases inside the cells accelerates the rate of diastolic membrane depolarization indirectly, but substantially, by activating an inward current of the Na + /Ca 2+ exchanger (I NCX ). When membrane depolarization reaches a threshold for activating voltagesensitive Ca 2+ channels, these open to produce a Ca 2+ current that generates the action potential upstroke. Finally, potassium currents become activated during the action potential, repolarizing the membrane. The action potential not only paces cardiomyocytes but also simultaneously 'feeds' (via Ca 2+ current) the intracellular local Ca 2+ oscillators with Ca 2+ , their oscillatory substrate, and resets their periods to prepare for the next duty cycle. The funny current acts in concert with I NCX to drive diastolic depolarization. Thus, like all biological systems, the pacemaker system exhibits functional redundancy to guarantee robust operation.
Both electrical and Ca 2+ cycling events are regulated by common chemical signaling pathways. These include Ca 2+ activation of calmodulin-dependent kinase II and adenylyl cyclases to generate cAMP, which activates protein kinase-A. The resulting enhanced protein phosphorylation coordinates functions (e.g., activation kinetics) of intracellular and cell-surface proteins, resulting in crosstalk that is required for robust generation of rhythmic action potentials. Thus, Ca 2+ and these regulatory molecules are critical nodes within the system that link to redundant pacemaker mechanisms to insure fail-safe pacemaker operation. Importantly, these nodes remain active to keep the heart rate near the middle of its full range even in the absence of autonomic receptor stimulation. In response to signals that call for a change in heart rate, the system's nodes are adjusted by neurotransmitter activation of β-adrenergic and cholinergic receptors to effect functional changes in the different the period between heartbeats-the plasma membrane of pacemaker cells undergoes a slow spontaneous depolarization. When this depolarization reaches a critical level (excitation threshold), an all-or-none electric impulse (action potential) is generated within and between pacemaker cells. The action potential propagates across the atrium and enters conduction pathways that lead to the ventricle, where it stimulates the contraction of ventricular myocytes that expulses blood from the heart. Understanding of this pathway led researchers to believe until recently that pacemaker activity is fully controlled by electrogenic molecules, namely ion channels. This idea was bolstered by the work of Hodgkin and Huxley on membrane ion currents that generate nerve impulses (recognized by the 1963 Nobel Prize in Physiology or Medicine), and it inspired many extensive studies aimed at discovering the specific ion currents that drive spontaneous depolarization of the pacemaker-cell membrane.
This research showed that pacemaker cells lack the inward rectifier potassium current I K1 that keeps the membrane of ventricular myocytes strongly polarized to prevent spontaneous depolarization. Pacemaker cells were found to exhibit a nonselective 'funny' current, I f , which is activated when the membrane repolarizes and diastolic depolarization begins. I f seemed to be the long-sought ion current that controls diastolic depolarization and was often referred to as 'the pacemaker current' . Early efforts to create biological pacemakers were focused on increasing I f (ref.
3) or suppressing I K1 (ref. 4) . Surprisingly, this straightforward approach was insufficient to transform non-pacemaker cardiac cells into robust, responsive pacemaker cells.
More recent studies of cardiac pacemaker function have revealed a greater complexity that is not simply electrical. A 'symphony' of locally distributed molecules is involved in the pacemaker cell's electrical and chemical oscillations 5 (Fig. 1) . Specifically, the sarcoplasmic reticulum-a network of intracellular Ca 2+
The heartbeat is initiated by electrical impulses from specialized pacemaker cells in the sinoatrial node. If the pacemaker fails, the heart rate becomes abnormally low or irregular, leading to possible syncope and life-threatening circulatory collapse. In this issue, Kapoor et al. 1 demonstrate a strategy for restoring pacemaker activity by reprogramming working cardiomyocytes. They show that delivering a gene important in pacemaker development into the heart of guinea pigs converts cardiomyocytes into functional pacemaker cells. If this approach can be translated to the clinic, it would likely provide an improved therapeutic option for millions of people suffering from pacemaker failure.
Currently, pacemaker dysfunction is treatable only by implantation of an artificial pacemakera small electronic-pulse generator with leads attached to the heart. These devices are often associated with complications and limitations. Each year in the United States, ~200,000 artificial pacemakers are implanted and ~175,000 require replacement, removal or repair. In pediatric patients, pacemakers have to be adjusted in additional operations as the heart and body grow. To overcome the shortcomings of pacemaker therapy, in the past decade researchers have investigated the possibility of creating 'biological pacemakers' by deriving pacemaker cells from non-pacemaker cells through genetic engineering 2 . So far, the success of these approaches has been limited. To understand why, and to appreciate the future prospects of this emerging biotechnology, we need to look more closely at how the heartbeat is initiated.
At first glance, pacemaker activity appears to be wholly electrical in nature. During diastole- In addition to adding or removing ion channels, efforts to create bio-pacemakers have also manipulated cells at a systems level, for example, by overexpressing β-adrenergic receptors 6 (which receive and transfer neurotransmitter signals) or adenylyl cyclases (which generate cAMP). Most recently, overexpression of a Ca 2+ -activated adenylyl cyclase was shown to be sufficient, in the absence of funny-current activation, to produce biological pacemaking for 7 days in experimental dogs 7 .
Reprogramming paces the heart
It is likely that the most successful approach to creating biological pacemakers will recapitulate embryonic development, borrowing the transcription factors used by nature, such as members of the Tbx family. A recent study showed that Tbx3 reprograms mouse cardiomyocytes into pacemaker-like cells in vitro 8 . In the present report, Kapoor et al. 1 used neonatal rat ventricular myocytes to test the reprogramming capacity of five transcription factors known to be expressed in developing cardiac and pacemaker cells and found that Tbx18 was most effective. Transduction of bicistronic adenoviral vectors expressing Tbx18 generated persistent biological pacemakers (for up to 8 weeks) not only in cell culture but, importantly, in intact guinea-pig myocardium (in a small area of the ventricle near the injection site).
The reprogrammed cells, which the authors call induced sinoatrial node (iSAN) cells, exhibited the morphology and the major functional properties of natural pacemaker cells. These include downregulation of I K1 channels, expression of funny channels, and increased levels of cAMP to activate both funny channels and cAMP-dependent, protein kinase A-mediated phosphorylation of phospholamban, which accelerates Ca 2+ cycling by the sarcoplasmic reticulum. Several other features of pacemaker activity were documented, including generation of rhythmic diastolic local Ca 2+ releases that cause rhythmic spontaneous diastolic depolarizations leading to rhythmic action potentials. The cells also responded to various stimulations that mimic neurotransmitter signals with an appropriate increase or decrease of action potential firing rate, and their rate and rhythm depended on protein phosphorylation.
Future research on this approach could investigate several questions left unanswered by Kapoor et al. 1 . Many experiments were done in neonatal rodent myocytes (in vitro) and in rodents (in vivo), and these should be extended to adult cells and larger mammals. Long-term evaluation beyond 8 weeks is important because persistent higher cAMP levels, which would affect expression of numerous genes regulated by cAMP-dependent phosphorylation, may have undesirable effects, such as promoting cell death or some types of neoplasm 9 . cAMP levels are higher in pacemaker cells than in ventricular myocytes and are maintained by a relatively higher rate of turnover by adenylyl cyclases and phosphodiesterases. This allows effective regulatory changes in cAMP signaling in response to changes in Ca 2+ levels. To counteract the potential deleterious effects of higher cAMP levels, pacemaker cells have mechanisms that protect against cell death. It will be interesting to learn more about the pathways underlying the higher cAMP levels in iSAN cells and whether these cells have similar protective mechanisms. Another question for future research concerns the nature of the electrical coupling between iSAN cells and the host heart. Finally, overexpression or co-expression of transcription factors other than Tbx18 and Tbx3, such as Tbx5 and Shox2 and factors involved in earlier stages of cardiac cell catecholamine synthesis 10 , may also prove useful. Figure 1 The coupled-clock pacemaker 'symphony'. Regulatory factors or nodes (indicated in red) couple intracellular Ca 2+ to cell-surface proteins to generate rhythmic spontaneous action potentials at rest. b-adrenergic and cholinergic receptor activation change the action potential firing rate by signaling through the same nodes. The sequence of ion-current activation relative to the action potential is shown in the inset. This sequence, which is required for rhythmic and robust pacemaker function, includes signals from both the cell membrane (colored notes) and the intracellular calcium clock (Ca 2+ release channel, black note). GPCR, G protein coupled receptor; PKA, protein kinase-A; CaMK-II, calmodulin-dependent protein kinase II; I K , delayed rectifier K + current: I CaL , L-type Ca 2+ current; I NCX , Na + /Ca 2+ exchanger current; I f , nonselective funny current. 
